CORRECTING and REPLACING Pharmacyclics/Janssen Biotech's PCI-32765 Has Earned …MarketWatch (press release)Rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will continue to dominate a more fragmented diffuse large B-…
Juvenile arthritis affected kids are at a high risk of cancer: StudyNews-Medical.net… TNF inhibitors (etanercept, infliximab, or adalimumab); and other immunomodulatory agents (abatacept, alefacept, anakinra, azathioprine, cyclophosphamide, cyclospor…
Hematologic Cancers in Pregnancy Pose Substantial RisksMedscape"In contrast, aggressive lymphomas should be treated with no delay, and can be managed relatively safely by administrating the CHOP [cyclophosphamide, doxorubicin, vincristine, and pre…
In Vivo Studies Show CD137 mAb Agonist Boosts Anticancer Activity of TrastuzumabGenetic Engineering NewsRather, the CD137 agonist boosted the ability of NK cells activated using trastuzumab-coated breast cancer to kill rituximab-coated lymphoma cells. …
JIA Cancer Rates Not Linked to MedicationFamily Practice News Digital Network… TNF inhibitors (etanercept, infliximab, or adalimumab); and other immunomodulatory agents (abatacept, alefacept, anakinra, azathioprine, cyclophosphamide, cyclosporine, ef…
Splenic Lymphomas: Is There Still a Role for Splenectomy?Cancer NetworkIncreasing experience with rituximab (Rituxan), however, suggests that it may be reasonable to reconsider the role of splenectomy as frontline therapy for SMZL. Ultimately, the prac…
ImmunoCellular And Cancer Treatment's Next FrontierSeeking AlphaRituximab, (sold under the trade names Rituxan and MabThera) and developed and marketed by Biogen Idec (BIIB) has also garnered success in the treatment of many forms of leukemia and l…
MMRGlobal Goes Into 2012 Highlighting $43 Million in Projected Revenues From …MarketWatch (press release)… has more than 40 patents issued, pending and or applied for worldwide, including patents pertaining to the Company's FavId(R)/Specifid(TM…
BiovaxID® Personalized Lymphoma Vaccine is Featured in Article Published in …EON: Enhanced Online News (press release)According to the article, “This vaccine (BiovaxID) opens new doors because, as great a drug as rituximab is, even in combination …
BiovaxID(R) Personalized Lymphoma Vaccine is Featured in Article Published in …MarketWatch (press release)According to the article, "This vaccine (BiovaxID) opens new doors because, as great a drug as rituximab is, even in combination with chemo…